Home » Merck/Schering-Plough Backpedals on Vytorin Trial Endpoint
Merck/Schering-Plough Backpedals on Vytorin Trial Endpoint
A U-turn by Merck/Schering-Plough Pharmaceuticals over the primary endpoint of a controversial trial with the joint venture’s combination cholesterol management drug Vytorin/Inegy (simvastatin + ezetimibe) has done little to quell speculation over potential data manipulation in the ENHANCE study — or, indeed, over whether Vytorin offers any real clinical benefit compared with statin monotherapy.
PharmaTimes
PharmaTimes
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May